Sign In
Buy GILD
$125.16
+0.110 (+0.0880%)
At Close: Jun 24, 2026
Gilead Sciences, Inc. (GILD) Wells Fargo 2024 Healthcare Conference (Transcript)
11:47am, Friday, 06'th Sep 2024
Gilead Sciences, Inc. (NASDAQ:GILD ) Wells Fargo 2024 Healthcare Conference September 4, 2024 11:00 AM ET Company Participants Andrew Dickinson - Chief Financial Officer Conference Call Participants M
Gilead Sciences, Inc. (GILD) Morgan Stanley 22nd Annual Global Healthcare Conference (Transcript)
10:40pm, Thursday, 05'th Sep 2024
Gilead Sciences, Inc. (NASDAQ:GILD ) Morgan Stanley 22nd Annual Global Healthcare Conference September 5, 2024 12:20 PM ET Company Participants Daniel O'Day - Charman & CEO Andrew Dickinson - Chief Fi
Merck's Death Cross Vs. Gilead's Golden Cross: Pharma Giants Diverge On Wall Street
04:17pm, Tuesday, 03'rd Sep 2024
Merck & Co. MRK and Gilead Sciences Inc. GILD are two pharmaceutical heavyweights whose stocks tell very different stories.
Gilead Sciences Might Finally Be On Its Way To Higher Stock Prices
08:22am, Monday, 02'nd Sep 2024
Gilead Sciences reported good quarterly results and in the last few weeks, the stock rallied higher. Oncology will especially contribute to growth in the years to come, and maybe Gilead Sciences will
Gilead Sciences: Buy This Bargain Before It's Gone
02:53pm, Friday, 30'th Aug 2024
Since my last article, Gilead Sciences, Inc.'s stock price has continued to rise, thanks in part to strong sales of its HIV portfolio and an improved EBIT margin year-over-year. So, sales of the compa
Ipsen's Iqirvo Shows Strong Start in Primary Biliary Cholangitis, Now Faces Rivalry from Gilead's Livdelzi
02:14pm, Thursday, 29'th Aug 2024
Prior to the approvals and launches of Iqirvo and Livdelzi, US gastroenterologists notably favored the second to market Livdelzi as their preferred asset. Prior to the approvals and launches of Iqirvo
Here's Why a Handful of Pharmaceutical Stocks Rose Wednesday
07:01pm, Wednesday, 28'th Aug 2024
Shares of several drugmakers and biotechnology firms moved higher on Wednesday, notching some of the day's top performances in the S&P 500.
Gilead (GILD) Gains 16.8% in 3 Months: How Should You Play the Stock?
02:20pm, Monday, 26'th Aug 2024
While Gilead's (GILD) performance has been good in the past three months on robust second-quarter results and pipeline progress, we will wait before recommending the stock.
Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know
10:00am, Thursday, 22'nd Aug 2024
Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
10 Great Dividend Stocks For The Next 10 Years
09:00am, Saturday, 17'th Aug 2024
The focus of this article is to provide a select list of 10 dividend stocks that, in our view, are currently undervalued and should provide an average of 4.5% plus yield for the foreseeable future. We
Gilead (GILD) Obtains FDA Approval for PBC Drug Livdelzi
02:45am, Saturday, 17'th Aug 2024
Gilead (GILD) wins FDA nod for seladelpar for the treatment of primary biliary cholangitis (PBC) on an accelerated basis.
Gilead Sciences alleges dangerous drug-counterfeiting operation at two NYC pharmacies in lawsuit
08:30am, Friday, 16'th Aug 2024
Gilead Sciences says counterfeit versions of its HIV medications were being sold out of two New York pharmacies. Court documents alleged a twice-convicted medical fraudster wearing a court-ordered GPS
7 Defensive Stocks to Buy as Investors Seek Shelter
01:17pm, Wednesday, 14'th Aug 2024
Although the market may have hit a calm relative to the wild volatility witnessed earlier this month, we may not be out of the woods yet. Sure, the CBOE Volatility Index or the VIX has come down signi
US FDA approves Gilead's liver disease drug
01:11pm, Wednesday, 14'th Aug 2024
The U.S. Food and Drug Administration said on Wednesday it has approved Gilead Sciences' drug for a chronic and potentially fatal liver disease that mostly affects women.
3 Stocks Retirees Should Absolutely Love
06:50am, Saturday, 10'th Aug 2024
AbbVie offers reliable income and solid growth prospects. Bristol Myers Squibb is a stable dividend stock to buy and hold.
